Deep learning-derived splenic radiomics, genomics, and coronary artery disease

Meghana Kamineni (1), Vineet Raghu (2, 3), Buu Truong (4,5), Ahmed Alaa (6,7), Art Schuermans (4, 5, 8), Sam Friedman (9), Christopher Reeder (9), Romit Bhattacharya (10, 11), Peter Libby (12), Patrick T. Ellinor (4, 5, 13, 14), Mahnaz Maddah (9), Anthony Philippakis (15), Whitney Hornsby (4, 5), Zhi Yu* (4, 5), Pradeep Natarajan*(1,4,5,16)

* These authors jointly supervised this work.

Affiliations

1. Harvard Medical School, Boston, MA

2. Cardiovascular Imaging Research Center, Department of Radiology, MGH and HMS

3. Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Massachusetts

4. Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA

5. Center for Genomic Medicine and Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA

6. Computational Precision Health Program, University of California, Berkeley, Berkeley, CA 94720

7. Computational Precision Health Program, University of California, San Francisco, San Francisco, CA 94143

8. Faculty of Medicine, KU Leuven, Leuven, Belgium

9. Data Sciences Platform, Broad Institute of MIT and Harvard, Cambridge, MA

10. Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston MA 02114

11. Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA

12. Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115

13. Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, MA, USA

14. Demoulas Center for Cardiac Arrhythmias, Massachusetts General Hospital, Boston, MA, USA

15. GV, Cambridge, MA

16. Personalized Medicine, Mass General Brigham, Boston, MA

Please address correspondence to:

Zhi Yu, MB, PhD

75 Ames Street, Cambridge, MA 02142

617-714-7223

zyu@broadinstitute.org

Pradeep Natarajan, MD MMSc

185 Cambridge Street, CPZN 5.238, Boston, MA 02114

617-726-1843

pnatarajan@mgh.harvard.edu

Abstract

Background:

Despite advances in managing traditional risk factors, coronary artery disease (CAD) remains the

leading cause of mortality. Circulating hematopoietic cells influence risk for CAD, but the role

of a key regulating organ, spleen, is unknown. The understudied spleen is a 3-dimensional

structure of the hematopoietic system optimally suited for unbiased radiologic investigations

toward novel mechanistic insights.

Methods:

Deep learning-based image segmentation and radiomics techniques were utilized to extract

splenic radiomic features from abdominal MRIs of 42,059 UK Biobank participants. Regression

analysis was used to identify splenic radiomics features associated with CAD. Genome-wide

association analyses were applied to identify loci associated with these radiomics features.

Overlap between loci associated with CAD and the splenic radiomics features was explored to

understand the underlying genetic mechanisms of the role of the spleen in CAD.

Results:

We extracted 107 splenic radiomics features from abdominal MRIs, and of these, 10 features

were associated with CAD. Genome-wide association analysis of CAD-associated features

identified 219 loci, including 35 previously reported CAD loci, 7 of which were not associated

with conventional CAD risk factors. Notably, variants at 9p2 were associated with splenic

features such as run length non-uniformity.

Conclusions:

Our study, combining deep learning with genomics, presents a new framework to uncover the

splenic axis of CAD. Notably, our study provides evidence for the underlying genetic connection

between the spleen as a candidate causal tissue-type and CAD with insight into the mechanisms

of 9p21, whose mechanism is still elusive despite its initial discovery in 2007. More broadly, our

study provides a unique application of deep learning radiomics to non-invasively find

associations between imaging, genetics, and clinical outcomes.

Introduction

Introduction

Despite advances in the management of traditional risk factors, coronary artery disease (CAD)

remains the leading cause of mortality and disability-adjusted life-years (DALYs) worldwide.[1,2]

Advances in CAD prevention beyond targeting traditional risk factors continue to remain limited

due to poor understanding and limited mechanistic frameworks of such distinct CAD pathways.

The hematopoietic system has long been known to contribute to CAD, largely through

inflammatory cells in both atherogenesis and atherosclerotic cardiovascular disease events.[3]

Inflammation markers, such as high-sensitivity C-reactive protein (hsCRP), are independently

predictive of CAD risk. Among individuals with CAD and high hsCRP, a monoclonal antibody

targeting interleukin (IL)-1B reduced the risk for recurrent CAD events but increased risk for

serious infections.[4] While this trial validated the causal role of inflammatory cytokines for CAD,

the optimal strategy to modulate hematopoietic cells and their products toward CAD risk

reduction remains poorly understood.[5]

Longstanding circumstantial evidence has suggested involvement of the spleen, an

extramedullary hematopoietic organ, in CAD.[6] U.S. veterans who underwent splenectomy for

trauma during World War II had greater mortality due to CAD in long-term follow-up.[7] More

recently, the spleen was described as an important reservoir for undifferentiated inflammatory

myeloid cells that are mobilized in the context of myocardial ischemic injury infiltrating

myocardium in murine models.[8] Myelopoiesis after splenic activation, including during

myocardial infarction, further leads to atherosclerosis instability in mice.[9] Post-mortem human

samples from varying times after myocardial infarction demonstrate splenic monocyte depletion

early after myocardial infarction, invoking their mobilization early in the event.[10] (18)F-

fluorodeoxyglucose ((18)FDG)-positron emission tomography among patients who sustained

acute coronary syndromes showed that increased splenic metabolic activity strongly predicted

recurrence.[11] More recent human genome-wide association studies (GWAS) of CAD have

implicated splenic gene regulation. Individual inflammatory genes, including *CCR5*, prioritized

through this approach are strongly expressed in the spleen.[12] Among the top signals for CAD

GWAS, splenic tissue is one of the top three tissues enriched for variants residing within strong

enhancers and active promoters. However, there is limited understanding regarding the critical

factors regulating splenic function in relation to CAD risk.

Advancements in machine learning applied to medical imaging offer new opportunities

for unbiased, scalable detection and quantification of subtle alterations in internal organs,

including the spleen, where specific circulating biomarkers may be unavailable. Deep learning

enables large-scale automatic segmentation of organs in medical images, bypassing time-

consuming manual segmentation. Radiomics, an emerging field, quantifies features extracted

from these segmentations to offer non-invasive insights into underlying pathologies. These

features encapsulate a variety of metrics, such as shape, size, and texture.[13] For the spleen,

radiomics have been used to diagnose and differentiate lymphoma subtypes and predict the

recurrence of hepatocellular carcinoma.[14] Radiomics offers an opportunity to glean novel

insights about splenic anatomy as typically only splenic size is annotated in clinical scans.

In this study, we leveraged deep learning and radiomic analyses to extract and discover

CAD-relevant splenic features from abdominal magnetic resonance imaging (MRI). Additionally

using genomics, we further prioritize previously poorly known CAD-associated loci and genes

with key splenic radiomic features. Utilizing a multi-disciplinary approach that integrates

advanced imaging analyses, genomics, and clinical outcomes, our study introduces a new

framework for understanding the spleen's potential role in residual CAD risk.

Methods

Cohort selection and workflow

The UK Biobank is a volunteer cohort of approximately 500,000 participants aged 40-69 years

recruited from 2006 to 2010 with ongoing prospective follow-up.[15] At baseline, participants

provided surveys, biospecimens, anthropometrics, vital signs, and other study-specific

procedures. Approximately 50,000 MRIs were performed for a subset of participants after

reinvitation beginning in 2014. We limited our study population to those who had abdominal

MRIs acquired during the study and whose spleen and liver segments were identifiable after

applying our segmentation algorithm. Analysis of the UK Biobank data was approved by the UK

Biobank application 7089 and Massachusetts General Hospital IRB protocol 2021P002228. The

inclusion and exclusion criteria are visualized in **Supplemental Figure 1**.

Figure 1 illustrates the study workflow. First, we segmented the spleen from abdominal

MRIs and extracted comprehensive radiomic features linked to intrinsic splenic properties. Next,

we used regression models to discover independent splenic features associated with CAD, which

we investigated in subsequent analyses. We then performed GWAS to identify genetic variants

associated with each of the CAD-associated splenic phenotypes, building on which we (1)

prioritized genes that are likely to be causal and probed their functional relevance to CAD and (2)

identified overlapping genetic variants that are significantly associated with both splenic

phenotypes and CAD, whose corresponding functions may be the link between the spleen and

residual CAD risk.

Phenotyping of clinical and demographic variables

CAD was defined as a history of coronary artery bypass grafting, myocardial infarction (MI),

coronary artery angioplasty, or billing codes (OPCS-4: K40, K41, K45, K49, K50.2, K75) as

previously performed.[16] Prevalent and incident CAD status were defined by whether participants

were diagnosed with CAD before or after the time of their MRI. Demographic variables were all

ascertained at enrollment and included age, race, and sex of participants.

Genotyping and genome-wide association study

The genotyping procedures of the UK Biobank have been described previously in detail.[15] The

genotyping arrays were the UK BiLEVE Axiom Array or the UK Biobank Axiom Array (both

Affymetrix). The array-derived genotypes were imputed using the Haplotype Reference

Consortium, UK10K, and 1000 Genome reference panels. Variant quality control measures

included the following filters: MAF $\geq$ 1%, single nucleotide variant missingness <10% and HWE

P $\geq$ 10−15, MAC $\geq$ 50, and INFO score $\geq$0.6. Sample quality control measures included

excluding individuals if the single nucleotide variant missingness was equal to or exceeded 10%.

Association analysis was performed in participants of European ancestry using REGENIE with

adjustment for age, sex, and first ten PC of genetic ancestry.

Extraction of splenic features

Briefly, the UK Biobank abdominal MRI protocol was as follows.[17] The study aimed to image

100,000 healthy UK participants aged between 40 and 69 years old. 1.5 T clinical MRI scanners

were utilized (Magnetom Aera, Siemens Healthineers, Erlangen, Germany) to acquire whole-

body T1-weighted dual echo gradient echo (GRE) sequences. The parameters were as follows:

echo times (2.39/4.77 ms), pixel size (2.23 × 2.23 mm2), slice thickness (3–4.5 mm), repetition

time (6.69 ms), and flip angle (10°). For each patient, four MRI contrasts were available: in-

phase (IP), out-of-phase (OP), water, and fat. We downloaded all abdominal MRIs from the UK

Biobank.

We then used deep learning to segment spleens from abdominal MRIs of our study

population and extracted 107 splenic radiomic features. Briefly, we used a stitching algorithm to

stitch together MRI scans from six acquisition stations and compose whole-body scans outputted

as four phases: water, fat, in phase, and out of phase (https://github.com/biomedia-

mira/stitching).[34] Utilizing a pre-trained nnuNet segmentation model, originally trained on

10,000 UK Biobank abdominal MRIs, we generated predictions of voxels corresponding to the

spleen (code: https://github.com/BioMedIA/UKBB-GNC-Abdominal-Segmentation, trained

models: https://gitlab.com/turkaykart/ukbb-gnc-abdominal-segmentation).[18] This model had no

errors in over 95% of the spleen segmentations in the UK Biobank data, and we performed no

additional training. The models utilize a nnU-net architecture, a variant of the popular U-Net

architecture that was shown to outperform U-Net on a range of biomedical imaging segmentation

tasks. The models were validated in a previous study using 400 previously labeled images.[18] The

inputs to the model were water, fat, in- and opposed-phase stitched MRss. The model was

applied on a Google Cloud Platform with CUDA version 11.6 and with 2 Tesla T4 GPUs

available with 16 GB RAM each. Lastly, we extracted the voxels that corresponded to the spleen

segment.

We applied the *pyradiomics* software (version 3.1.0) to the voxels identified by the model

as spleen segments to extract shape and texture-based features.[21] Generation of these features

includes first-order statistics describing the image region and computation of the relationships

between neighboring pixels. All code was parallelized using multi-processing to decrease

runtime. In addition to the features extracted through this approach, we utilized the splenic

volume features provided by the UK Biobank, which was determined using a deep learning U-

net architecture as described in this study.[22]

Correlation of splenic features with each other and cardiometabolic outcomes

We examined the associations of splenic features with age, sex, and BMI

(https://biobank.ctsu.ox.ac.uk/showcase/field.cgi?id=21001). We used a linear regression model

with each splenic feature as the independent variable and age at enrollment, sex, BMI, and days

between enrollment and MRI acquisition as dependent variables. All splenic radiomic features

were normalized to a distribution with mean 0 and standard deviation 1 for all analyses. We

reported the coefficients and standard errors of both BMI and sex for each splenic feature.

We also associated the splenic features with blood-based biomarkers available in the UK

Biobank. Blood-based markers include counts and percentages of basophils, eosinophils,

lymphocytes, monocytes, neutrophils, platelets, reticulocytes, high light scatter reticulocytes,

white blood cells, red blood cells, and nucleated red blood cells. Other biomarkers were C

reactive protein, hematocrit, hemoglobin concentration, immature reticulocyte fraction, mean

corpuscular hemoglobin, mean corpuscular hemoglobin concentration, mean corpuscular,

platelet, reticulocyte, and sphered cell volumes, and platelet and erythrocyte distribution width

(https://biobank.ndph.ox.ac.uk/ukb/label.cgi?id=9081). For each of the blood-based biomarkers,

we implemented a linear regression model with each splenic feature as the outcome and the

biomarker as a covariate and adjusted for age, sex, BMI, and the days between enrollment and

the MRI acquisition. We then reported the coefficient, which can be interpreted as the change in

one unit of the biomarker per 1 SD of the radiomic feature, and standard error of the biomarker

in the model.

Identification of splenic features associated with CAD

We examined for splenic radiomic features that are associated with CAD outcomes. We

differentiate between CAD diagnosed prior to MRI (prevalent cases) for assessing splenic

markers of existing CAD, and first CAD after MRI (incident cases among those without

prevalent CAD) for assessing splenic predictors of future CAD. We performed feature

processing before training two models for the outcomes of prevalent and incident CAD. Race

and sex were coded as binary indicator variables. For each feature, we imputed any missing

values with the median of all values for the feature, since missingness was less than 10%. We

then employed forward selection to identify independent features for each CAD outcome,

thereby minimizing potential collinearity. Starting with all features including splenic features,

age, race, and sex, this method selected features one at a time that had a P value of less than a

threshold when added to a model with already included features

(https://github.com/AakkashVijayakumar/stepwise-regression/tree/master). We selected this

threshold using 5-fold cross-validation on a held-out validation set, and our threshold options

were 0.025, 0.05, 0.1, and 0.2. After a subset of features was selected, we standardized all

features to normal distributions.

Subsequently, we analyzed the associations between the selected radiomic features and

CAD outcomes using L1-regularized multivariable regression models, specifically logistic

regression and Cox proportional hazards for prevalent and incident CAD respectively. For each

model, 70% and 30% of the data were utilized for training and evaluation respectively. To

identify splenic features associated with prevalent CAD, we trained an L1-regularized logistic

regression model for the outcome of prevalent CAD. We optimized the logistic regression model

using a 5-fold cross-validation grid search for various hyperparameters, including different

regularization parameters (C = [5×10^{-5}, 5×10^{-4}, 5×10^{-3}, 0.05, 0.5, 1, 5, 10]), maximum number

of training iterations (max_iter = [1000, 5000]), and reweighting of data points to minimize class

imbalance (class_weight = [balanced, None]). We computed AUROC to evaluate the logistic

regression. For the outcome of incident CAD, we used a Cox proportional hazards model in

order to account for the temporal information of time from MRI acquisition to CAD diagnosis.

The time event was the days from MRI date to CAD diagnosis, and patients with CAD diagnosis

before MRI date were excluded from the analysis. We computed concordance and AIC to

evaluate the model. To ascertain the robustness of our findings, we performed 1000 resamplings

using Monte Carlo bootstrapping on the test set to calculate 95% CI of the AUROC or

concordance index.

Genome-wide association study and gene prioritization

We explored the genetic underpinnings of CAD-associated splenic features by conducting

GWAS on common variants (minor allele frequency > 0.01) for the fourteen splenic radiomic

features. We used the PLINK (version 2.0) and REGENIE (version 3.2.8) software to run a

GWAS for each splenic feature for chromosomes 1-22. We used a minor allele frequency of 0.01,

missingness upper threshold of 0.1, and Hardy-Weinberg equilibrium value of $1*10^{-15}$. We

adjusted for age, sex, first ten genetic PCs, and genotyping array. For all phenotypes, we

computed the genomic inflation factor and the LD score intercept using LD Score Regression

(LDSC) using LD scores from participants of European ancestry from the hapmap3 variants.[23]

To further analyze the results, we used the Functional Mapping and Annotation of

Genome-Wide Studies (FUMA), a platform for annotation of GWAS results and gene

prioritization.[24] Independent, significant loci were detected based on a significance threshold of p

$< 5*10^{-8}$ and clumping with 1000 Genomes data, with an R^2 threshold of 0.6. Lead SNPs were

then detected based on clumping on independent, significant loci with an R^2 threshold of 0.1. We

used an online list comparator to identify overlapping lead SNPs

(https://molbiotools.com/listcompare.php). For gene prioritization, we used FUMA to identify

the nearest genes to each SNP and the genes prioritized by expression quantitative trait loci

(eQTL).[24] The nearest gene to each SNP was identified using a window of 10 Kb of the SNP. We

combined the PoPS analysis with positional mapping in order to prioritize genes, as combining

similarity-based and locus-based approaches has been shown to lead to better identification of

causal genes.[25] To implement PoPS, we first computed MAGMA scores from the summary-level

results of the GWAS with each splenic feature. We then computed a PoPS score for all genes

within 10 Kb of the significant SNPs. We selected the gene with the highest PoPS score in each

locus. All GTEx v7 eQTL data were used for eQTL mapping, specifically adipose tissue, adrenal

gland, blood, blood vessel, brain, breast, colon, esophagus, heart, liver, lung, muscle, nerve,

ovary, pancreas, pituitary, pancreas, salivary gland, skin, small intestine, spleen, stomach, testis,

thyroid, uterus, and vagina tissues. In order to prioritize genes using PoPS, we processed publicly

available features derived from gene expression data from various organs

(https://github.com/FinucaneLab/gene_features). For the GWAS results for each splenic

phenotype, we then applied MAGMA, which provides gene-level association statistics. Finally,

we applied the PoPS algorithm to derive scores for each gene.[26] We stratified the genes by

genomic locus and prioritized the gene with the highest PoPS score. For each splenic phenotype,

we filtered genes prioritized by at least two of the three methods. We then compiled all genes

prioritized in this manner for any of the ten splenic phenotypes.

From the genes prioritized for the splenic phenotypes, we used OpenTargets to identify

genes associated with CAD. Associations with CAD are based on a combination of scores based

on data from Open Targets Genetics, ClinVar, an NIH public archive of the relationship between

human genetic variants and phenotypes, and other genetic sources (https://platform-

docs.opentargets.org/evidence#open-targets-genetics). We included all genes as associated with

CAD if the overall association was greater than 0. For the genes with non-zero associations with

CAD, we then searched for the mouse phenotypes in mice where the gene was knocked out using

the International Mouse Phenotyping Consortium, a collaboration between 21 research

institutions where approximately 20,000 genes are systemically knocked out one by one in mice

to understand the resulting phenotypes.[27,28]

Overlap of SNPs and genetic correlation between splenic phenotypes and CAD

We used GWAS results from a previous meta analysis for CAD for determining overlap and to

identify genetic correlation.[29] We identified SNPs that were significantly associated with both

CAD and at least one of the six splenic phenotypes. We used a p-value threshold of $<5\times10^{-8}$ to

define significant SNPs for both the CAD and splenic phenotype GWAS results. For each

splenic phenotype, we clumped the significant SNPs overlapping with CAD using 1000

Genomes reference panel of European participants to identify lead SNPs.[23,30] After filtering to

SNPs meeting the genome-wide significance threshold, clumping of SNPs was performed using

the default settings of 0.0001 as the significance threshold for index SNPs, 0.01 as the threshold

for clumped SNPs, 0.50 as the LD threshold, 250 kb as the distance threshold, and 1000

Genomes patient cohort as the reference population. Next, we investigated the phenotype

associations of the lead SNPs using PhenoScanner, a database that contains over 65 billion

phenotype associations and 150 million unique variants.[31,32] To compute genetic correlation, we

used existing heritability estimation software and 1000 Genomes European LD score data.[23,30,33]

Results

Study population

Our study included 42,059 participants in the UK Biobank study who had abdominal MRIs

without known hematological cancer at the time of MRI (**Supplemental Figure 1**). The study

population at enrollment had a mean age of 55.1 years (standard deviation [SD] 7.5), body-mass

index (BMI) of 26.1 kg/m^2 (SD 4.2), comprised 52.1% females (N=21,895), and was

predominantly of British White ancestry by self-report (96.7%, N=40,675). At MRI

ascertainment, the prevalence of CAD, hypertension, hyperlipidemia, and type 2 diabetes was

4.7% (N=1,987), 24.0% (N=10,082), 16.7% (N=7,010), and 3.0% (N=1,243), respectively. The

median time from UK Biobank enrollment to MRI was 9.4 years [IQR: 6.8-12.0], and the

median follow-up time after MRI was 5.00 years [IQR: 3.85-6.63]. Key hematologic parameters

measured at enrollment showed a mean white blood cell count of 6.6×10^9 cells/L (SD: 1.6),

hemoglobin concentration of 14.2 g/dL (SD: 1.2), platelet count of 249.9×10^9 cells/L (SD: 56.3),

and hsCRP levels at 2.1 mg/L (SD: 3.6) (**Table 1**).

Deep learning-extracted radiomic characteristics of the spleen

In our study population, splenic volume was previously annotated by the UK Biobank centrally

for 15,215 participants with a mean of 0.17 liters (SD 0.07). Splenic volume varied with age and

sex. It decreased modestly with age in this middle-aged cohort, from 0.18 mg/g (SD: 0.07)

among individuals aged 40-48 years to 0.16 mg/g (SD: 0.07) among those aged 62-70 years.

Splenic volumes on average were lower in women (mean 0.14 mg/g, SD 0.05) compared to men

(mean 0.19 mg/g, SD 0.07).

We generated spleen images from the first MRI for all 42,059 participants. We extracted

107 radiomic features using the pyradiomics software (version 3.0.1).[21] Features are grouped into

first order statistics, 3D shape-based features, and five categories of gray level information

(**Figure 2** and **Supplemental Table 1**).

We extracted 18 first-order statistics that indicate the distribution of voxel intensities

within the masks of the image region. These features capture the magnitude, randomness,

uniformity, and asymmetry of the voxel values, as well as standard descriptors such as mean,

median, and range.

We derived 14 shape-based 3D metrics gleaned from the approximated shape defined by

the triangle mesh independent of gray-level intensities using a 'marching cubes' algorithm.[35]

These features are readily interpretable. As expected, several volume-related features, including

mesh volume, voxel volume, major and minor axis lengths, and surface area are highly

correlated with the annotated volume which was measured by the UK Biobank as part of the

imaging exam (Pearson correlation coefficients [ρ] ranging from 0.70 to 0.99; all P<0.001). In

contrast, morphologic measures such as sphericity, elongation, and flatness exhibited relatively

lower or no correlation with the annotated volume ($\rho < 0.25$), indicating their orthogonal

informational value (**Supplemental Table 2**).

The remaining 75 features focused on texture metrics relating to gray levels. We

extracted gray level co-occurrence matrix (GLCM) to measure pixel intensity pairings within a

spatial context, the gray level size zone matrix (GLSZM) to count interconnected voxels zones of

similar grayness, and the gray level run length matrix (GLRLM) to assess the spatial

distributions of these zones, reflecting graininess. 16 features were generated using each of these

matrices. The neighboring gray tone difference matrix (NGTDM) estimates the variations in gray

value over a specified distance for 5 features, and the gray level dependence matrix (GLDM)

gauges the connectivity of voxels relative to a center voxel across 14 features. **Supplemental**

Figure 2 shows Pearson correlation coefficients between features, and further details are in

https://pyradiomics.readthedocs.io/en/latest/features.html and **Supplemental Table 1.**

Splenic radiomics with other variables

Given the known influences of age, sex, and obesity on splenic function, we examined

the association of age, sex, and BMI (after adjustment for the others) with each splenic feature

using multivariable linear regression and observed many significant associations. In particular,

sex showed the strongest associations with splenic size including minor axis length (0.7 SD

lower in females vs males, 95% CI [0.68,0.72]) and surface area (0.70 [0.68,0.72]). BMI was

most significantly associated with several texture features: one unit increase in BMI was

associated with 0.11 [95% CI: 0.10, 0.11], 0.09 [0.09, 0.10], 0.09 [0.09, 0.09] SD increase in

GLSZM gray level non-uniformity, run length non-uniformity, and GLRLM gray level non-

uniformity, respectively (**Figure 3** and **Supplemental Figure 3**).

We then examined the associations between splenic features and hematologic biomarkers,

adjusting for age, sex, and BMI. The strongest associations were of energy and GLSZM size

zone non-uniformity exhibited with high light scatter reticulocyte count, with an increase of 0.21

[95% CI: 0.21, 0.21] per 1 SD of each radiomics feature. Many splenic features were negatively

associated with mean spherical cell volume, including surface area (**Supplemental Figure 4**).

The strongest association for white blood cell (WBC) count was a 0.10 [0.09, 0.11] increase for 1

SD increase of GLCM informational measure of correlation 1. For red blood cell count, a 0.16

[0.15, 0.17] increase was associated with 1 SD increase of GLSZM size zone non-uniformity.

For C-reactive protein, a 0.05 [0.03, 0.06] increase was associated with 1 SD increase of median.

Supplemental Table 3 contains the top splenic radiomic features associated with each

hematological parameter.

Prioritizing CAD-associated splenic radiomics

For prevalent CAD, the optimized regression model achieved an AUROC of 0.77 (95%

CI 0.75-0.78) in the held-out test set (N=12755), and the Cox model for incident CAD yielded a

concordance index of 0.68 (95% CI 0.65-0.71) in the test set (N=12022). Notably, 9 and 5

splenic radiomic features were retained in the prevalent and incident CAD models, respectively,

achieving statistical significance (P<0.05) after adjustment for other covariates.[36] There is no

overlap in significant splenic features between prevalent and incident CAD. For prevalent CAD,

associated features included GLSZM gray level non-uniformity (OR per 1 SD increase: 1.59 [95%

CI: 1.38, 1.82], P<0.001, FDR<0.001) and sphericity (OR: 1.16 [95% CI: 1.09, 1.23], P<0.001,

FDR<0.001), among others. GLCM correlation, energy, GLDM metrics of small dependence

high gray level emphasis and gray level variance, GLSZM large area low gray level emphasis,

GLRLM run length non-uniformity, and GLCM inverse difference also showed significant

associations with prevalent CAD. For incident CAD, associated features included GLRLM run

length non-uniformity (HR: 1.17 [95% CI: 1.09, 1.25], FDR<0.001), which was also associated

with prevalent CAD, and GLCM inverse difference normalized (HR: 0.90 [95% CI: 0.85, 0.95],

FDR<0.001) (**Supplemental Table 4, Figure 4A-B**). All features significantly associated with

prevalent or incident CAD met the FDR threshold of 0.05 for significance for genetic discovery

and were used for subsequent analyses.

To examine the relationships between these CAD-associated splenic features and

conventional CAD risk factors, including age, sex, race, smoking, BMI, diabetes, hypertension,

and total, HDL, and LDL cholesterol levels, we calculated their pairwise Pearson correlations.

Gray level-uniformity, energy, and run-length non-uniformity are moderately positively

correlated with BMI and triglyceride levels, and all three features negatively correlate with HDL

cholesterol. Overall, most features exhibit only weak correlations with all conventional CAD risk

factors (**Figure 4C**). **Supplemental Figure 5** shows representative MRI images for the

prioritized splenic features.

219 genome-wide significant regions associated with CAD-associated splenic features

In the GWAS for the fourteen splenic radiomics features, there was no significant inflation of

association statistics (λ_{GC} ranges from 1.03 to 1.15; LD score intercept ranges from 1.03 to 1.17.

Supplemental Table 5). The genetic signals varied across the 14 traits. Using $P < 5*10^{-8}$ and r^2

< 0.1 as thresholds to identify significant and independent variants, we discovered 95

independent significant SNPs for sphericity, 72 for energy, 41 for GLRLM run length non-

uniformity, 21 for GLSZM gray level non-uniformity, and 16, 9, 7, 4, 2, and 0 for GLSZM large

area low gray level emphasis, GLCM inverse difference, GLCM inverse difference normalized,

GLCM correlation, GLDM small dependence high gray level emphasis, and GLDM gray level

variance, respectively. At the locus level, chr9:91392686, chr12:112037450, chr12:112007756,

and 12:113165247 were all associated with 4 splenic features respectively; a few other

discovered loci also associated with more than one feature, but more were associated with unique

traits (**Figure 5, Supplemental Figures 6-14**).

Utilizing GWAS results of CAD-associated splenic features, we assessed their genetic

correlations with CAD, observing varying degrees of correlations. The features with the

strongest correlations that had the same direction of effect on CAD as in the regression models

were GLCM correlation (r_g=0.17, P=0.002) and energy (r_g=-0.12, P=0.01), indicating shared

genetic basis with CAD. A few features had more modest genetic correlations with CAD,

suggesting the need for studying the non-genetic pathways linking them with CAD

(**Supplemental Table 15**).

THBS1, PDE5A, and 35 more CAD-associated genes are likely to be causal genes for splenic

features

For GWAS of each CAD-associated splenic feature, we prioritized genes likely to be causal

using three methods: 1) gene annotation based on distance (i.e., nearest gene), 2) polygenic

priority score (PoPS), and 3) eQTL mapping based on cis-eQTLs. These loci mapped to 83, 58,

35, 21, 16, 9, 7, 4, 2, 0 respective genes based on proximity, by choosing the closest gene to each

SNP within 10 Kb, for the splenic phenotypes listed in the order from the previous section

(**Supplemental Tables 6-14**). The strongest signals for sphericity and GLDM small dependence

high gray level emphasis were annotated to *TLX1NB* and *LRRC37A2:ARL17A,* and the signals

for the other features were near *ATXN2,* a multi-functional gene linked to circadian rhythm and

neurodegenerative diseases and prioritized in a previous GWAS for splenic volume.[22,37]

Using PoPS, we prioritized 0 to 48 genes per feature, with top putative causal genes

including *S1PR3*, *ARHGAP42*, *SMG6*, [38]*IRS1*, and *THBS1*, which were prioritized for 3 or more

splenic features. *S1PR3* encodes a lysophospholipid mediator that has been shown to have both

protective effects against stroke and vasoconstrictor effects.[39] We observed strong corroboration

between prioritized genes by PoPS (similarity-based approach) and distance (locus-based),

increasing confidence in the results (**Supplemental Tables 16-24**).[26] Using eQTL data from

GTEx v7,[40] top genes prioritized by eQTL mapping prioritized include *S1PR3*, *EGF*, *HECTD4,*

ARHGAP42, *NAA25*, and *SMG6*, which were all prioritized for at least 4 splenic features, and are

similar to those prioritized by nearest genes and PoPS (**Supplemental Tables 16-24**).

Collectively, 119 genes were prioritized by at least two gene prioritization methods across all

phenotypes (**Supplemental Table 25** and **Figure 6).**

We explored the functional implications of genes prioritized for their links to CAD,

leveraging OpenTargets to assess their CAD associations and the availability of targeted

therapies. Among these, 37 genes, including *EGF, HECTD4, ARHGAP42, NAA25, SMG6, RPL6,*

IRS1, THBS1, PDE5A, FTTO, PPARG, CUX2, have established CAD associations based on

various genetic data sources (**Supplemental Table 25, Methods**).[31,32] These genes are involved

in multiple mechanisms, including inflammation (e.g., *THBS1*), smooth muscle cell regulation

(e.g., *TCF21*, *PDE5A*), hypertension (e.g., *HECTD4, ARHGAP42*), heart tissue development

(e.g., *WNT5A*, *HAND2*, *TCF21*), and adipogenesis (e.g., *FTO, PPARG*). We traced back the 37

genes to our GWAS across splenic features and found many were discovered from energy, run-

length non-uniformity, and sphericity GWAS (**Supplemental Table 25**). For each gene, we

identified mouse phenotypes resulting from gene knockout using the International Mouse

Phenotyping Consortium.[27,28] Knocking out *SMG6*, *PDE5A*, and *TCF21* resulted in abnormal

spleen morphology, enlarged spleens for *SMG6* and *PDE5A,* and small spleens for *TCF21*.

TCF21 knockout led to abnormal blood vessels. *THBS1* knockout led to abnormal and enlarged

hearts (**Supplemental Table 25**).

Overlap of SNPs and genetic correlation shed light on the link between splenic phenotypes and

CAD

Utilizing previously published CAD GWAS,[29] we compiled SNPs associated with CAD and

identified the ones associated with splenic features. 396 and 390 CAD-associated SNPs were

associated with energy and run-length non-uniformity respectively, and the overall median [IQR]

number of SNPs associated with CAD and the splenic features was 255.5 [18, 337]. After

clumping of SNPs, 24 and 22 independent CAD-associated SNPs were significantly associated

with energy and run-length non-uniformity, respectively. The overall median [IQR] number of

SNPs associated with CAD and the splenic features was 9 [3, 17], with 39 unique ones across all

splenic phenotypes (**Supplemental Table 26**). We filtered to 35 lead SNPs where the effect

direction of the SNP on CAD was consistent with the effect of at least one radiomic feature on

CAD risk.

We interrogated the existing associations of lead SNPs using PhenoScanner[31,32] to assess

for pleiotropic associations (**Supplemental Table 27**). Of the 35 SNPs, 7 (20%) were not

associated with any known cardiovascular risk factor, including hypertension, diabetes, systolic

and diastolic blood pressure, smoking, total, HDL, and LDL cholesterol, triglycerides, or weight

(**Supplemental Figure 15**). These SNPs were rs7036656 (chr9p21.3), rs56750693

(chr12q24.12), rs11515 (chr9p21.3), rs4239427 (chr18q11.2), rs4098854 (chr12q24.12),

rs1208250 (chr6q23.2), and rs1208258 (chr6q23.2). These SNPs were associated with GLSZM

gray non-uniformity, energy, GLSZM large area low gray level emphasis, GLRLM run length

non-uniformity, GLCM inverse difference, sphericity, and GLDM large dependence high gray

level emphasis.

The top SNPs at two identified loci, rs7036656 and rs11515, are at the chr9p21 locus, the

most strongly associated CAD locus but previously with limited mechanistic insight.[41] The

rs7036656 SNP is significantly associated with energy ($P=1.5\times10^{-20}$), GLRLM run length non-

uniformity ($P=1.6\times10^{-16}$), GLSZM large area low gray level emphasis ($P=8.0\times10^{-9}$), GLSZM

gray non-uniformity ($P=3.4\times10^{-9}$), and GLCM inverse difference ($P=3.2\times10^{-8}$). The rs11515

SNP is significantly associated with energy ($P=2.4\times10^{-11}$) and run length non-uniformity

($P=3.3\times10^{-9}$). Both loci are associated with energy and run-length non-uniformity. The strongest

signal in the GWAS for both energy and run-length non-uniformity was at the same locus,

rs653178 (energy: $P = 1.3\times10^{-106}$, Z score = 21.9; run_length non-uniformity: $P = 9.2*10^{-72}$, Z

score = 17.9; nearest gene: *ATXN2*), indicating further genetic overlap between the two

radiomics features. This locus is associated with systolic and diastolic blood pressure.[42]

Discussion

In this study, we harnessed deep learning to extract splenic phenotypes not readily quantifiable

through conventional methods, establishing the link between spleen and CAD. We discovered

several radiomic features, such as heightened sphericity, increased texture variation, and reduced

gray level intensity in the spleen, that were robustly associated with elevated CAD risk. We

explored the genetic underpinnings of these CAD-associated splenic features, providing insight

into the potential mechanism of the spleen's involvement in key processes related to CAD, such

as inflammation, smooth muscle cell regulation, and hypertension. Notably, we mapped seven

genetic loci unlinked to known CAD risk factors to the splenic features, offering potential new

targets for intervention and dissecting the splenic axis of CAD.

Our study has several implications. The first is that novel deep learning techniques to

non-invasively extract radiomic features in the spleen at scale enable association study and

genomic analysis of splenic variation in the population. This approach is particularly pertinent

for the spleen, an organ with limited annotations even in clinical reports. Furthermore, in our

study, the splenic radiomic features carry detailed information on shape, size, texture, and

intensity much beyond known splenic markers - except for volume-related splenic features

highly correlated with known splenic volume, other features provided orthogonal information

about the spleen. Lastly, the pipeline we built offers a scalable framework for extracting features

of other organs from imaging, facilitating the construction and testing of novel biomedical

hypotheses.

Second, we put the computer-learned features in a disease context and identified potential

radiomic markers for CAD. For example, image-derived texture variation has been used to

identify specific patterns within lymphoma, splenic infarction, and splenic cysts[43] ; specific to

splenic features, sphericity and flatness have previously been used to distinguish between

lymphoma subtypes.[14] Our work expanded their use to look across all splenic radiomic features,

capturing several aspects of spleen, and comprehensively examined the potential markers of

CAD. We also identified splenic features common to patients both before and after CAD

diagnosis, specifically run-length non-uniformity, suggesting that increases in splenic texture

variation occur before CAD diagnosis and persist after diagnosis. This finding provides evidence

that splenic changes are present with early development of CAD and are not simply effects of

later disease progression.

Third, we integrated genetics and yielded important discoveries on the potential

mechanism linking the spleen to CAD. Through GWAS and subsequent gene prioritization and

annotation, we identified causal genes of CAD-associated splenic features and found their strong

relevance in inflammation, smooth muscle cell regulation, and hypertension. For example, a top

prioritized gene *THBS1* is implicated in angiogenesis and inflammation; *PDE5A*, essential for

smooth muscle cell relaxation and linked to CAD through dysfunctional nitric oxide signaling

and the second messenger cGMP in atherosclerosis, and *TCF21*, a regulator of coronary artery

smooth muscle cell precursors, were prioritized.[44,45,46] Both *PDE5A* and *TCF21* knockouts in

mice affect gross spleen morphology, highlighting their relevance to both CAD and splenic

phenotypes and thus the validity of our findings.

Also, we identified 35 pleiotropic loci associated with CAD and splenic features, where

the effect of the locus on the radiomics feature and CAD was consistent. Among them, 7 were

not linked to any conventional CAD risk factors, suggesting orthogonal information of the

splenic axis of CAD; in particular, rs7036656 and rs11515 on the Chr9p21 locus, one of the

strongest CAD loci whose mechanism remained unclear since its initial discovery in 2007, is

identified in our study as associated with splenic texture changes, such as energy and run length

non-uniformity.[47] These findings, together, shed light on novel mechanisms linking the spleen to

CAD, providing potential targets for therapeutic intervention to address this unexplored axis.

Our study has limitations. Firstly, the UK Biobank cohort includes participants of mostly

European ancestry, and the participants were recruited between the ages of 40 and 59, limiting

the generalizability of our findings to other ancestries and younger patients. These results should

be replicated for a more diverse cohort. Second, we included participants whose MRI were

categorized as "high-quality" by the segmentation model and filtered out "low-quality" ones

where the spleen was not identified. However, those filtered images may contain unique

information that resulted in the classification. Third, to increase discovery power, we used a

more liberal CAD definition, and therefore some associated splenic features may not be directly

relevant to the etiology of strictly defined CAD.

In conclusion, by extracting novel splenic radiomics features linked to CAD and

uncovering their genetic underpinnings, our work examined the unaddressed splenic axis of

CAD. We demonstrated significant associations of splenic sphericity and texture variation with

CAD risk, alongside identifying genetic variants and prioritizing genes tied to these spleen-CAD

links. Leveraging several databases, we explored the functions of these genes and demonstrated

their relevance and potential mechanisms to CAD etiology. Notably, we highlighted several loci,

such as Chr9p21, linked to both splenic alterations and CAD yet unassociated with conventional

CAD risk factors, presenting them as potential novel targets for therapeutic intervention.

Together, our work presents a new framework to uncover the underexplored splenic axis of CAD.

Acknowledgments

We gratefully acknowledge the participants who provided biological samples and data for UK

Biobank. We also thank Mrs. Leslie Gaffney from the Broad Research Communication Lab for

her valuable assistance in improving the display items.

Funding

P.L. receives funding support from the National Heart, Lung, and Blood Institute

(1R01HL134892 and 1R01HL163099-01), the RRM Charitable Fund and the Simard Fund. P.N.

is supported by grants from the NHLBI (R01HL142711, R01HL127564, R01HL148050,

R01HL151283, R01HL148565, R01HL135242, and R01HL151152), National Institute of

Diabetes and Digestive and Kidney Diseases (R01DK125782), Fondation Leducq (TNE-

18CVD04), and Massachusetts General Hospital (Paul and Phyllis Fireman Endowed Chair in

Vascular Medicine). R.B. is supported by Harvard Catalyst K12 Award. V.K.R. is supported by

American Heart Association Career Development Award (935176). Z.Y. is supported by NHGRI

(K99HG012956-01).

Disclosures:

A.P. is a General Partner at GV. P.L. is an unpaid consultant to, or involved in clinical trials for

Amgen, AstraZeneca, Baim Institute, Beren Therapeutics, Esperion Therapeutics, Genentech,

Kancera, Kowa Pharmaceuticals, Medimmune, Merck, Moderna, Novo Nordisk, Novartis, Pfizer,

and Sanofi-Regeneron. P.L. is a member of the scientific advisory board for Amgen, Caristo

Diagnostics, Cartesian Therapeutics, CSL Behring, DalCor Pharmaceuticals, Dewpoint

Therapeutics, Eulicid Bioimaging, Kancera, Kowa Pharmaceuticals, Olatec Therapeutics,

Medimmune, Novartis, PlaqueTec, Polygon Therapeutics, TenSixteen Bio, Soley Thereapeutics, and XBiotech, Inc. P.L.'s laboratory has received research funding in the last 2 years from Novartis, Novo Nordisk and Genentech. P.L. is on the Board of Directors of XBiotech, Inc. P.L. has a financial interest in Xbiotech, a company developing therapeutic human antibodies, in TenSixteen Bio, a company targeting somatic mosaicism and clonal hematopoiesis of indeterminate potential (CHIP) to discover and develop novel therapeutics to treat age-related diseases, and in Soley Therapeutics, a biotechnology company that is combining artificial intelligence with molecular and cellular response detection for discovering and developing new drugs, currently focusing on cancer therapeutics. P.L.'s interests were reviewed and are managed by Brigham and Women's Hospital and Mass General Brigham in accordance with their conflict-of-interest policies. P.L. receives funding support from the National Heart, Lung, and Blood Institute (1R01HL134892, 1R01HL163099-01, R01AG063839, R01HL151627, R01HL157073, R01HL166538), the RRM Charitable Fund, and the Simard Fund. P.N. reports investigator-initiated grants from Amgen, Apple, Boston Scientific, Novartis, and AstraZeneca, personal fees from Allelica, Apple, AstraZeneca, Blackstone Life Sciences, Foresite Labs, Genentech, and Novartis, scientific board membership for Esperion Therapeutics, geneXwell, and TenSixteen Bio, and spousal employment at Vertex, all unrelated to the present work. P.N. is a scientific co-founders of TenSixteen Bio, and P.L. is an advisor to TenSixteen Bio. TenSixteen Bio is a company focused on clonal hematopoiesis but had no role in the present work. R.B. has been a advisor to Casana Care, Inc. unrelated to the current work. V.K.R has common stock in NVIDIA, Alphabet, Apple, and Meta. The other authors report no conflicts.

Table 1. Baseline characteristics. The number of incident and prevalent CAD cases in the

cohort is shown below, and the gender and race breakdown of the population is also presented.

For binary variables, metrics are represented as n (%). For continuous variables, age is

represented as mean (SD), and all other continuous metrics are reported as median (IQR). All

variables are measured at enrollment, unless an asterisk is included, indicating measurement at

MRI date or, in the case of incident CAD, measurement at any point after MRI date. CAD,

coronary artery disease. BMI, body-mass index. LDL, low-density lipoprotein. HDL, high-

density lipoprotein. CAD, coronary artery disease. BMI, body mass index. LDL, low-density

lipoprotein. HDL, high-density lipoprotein. *measured at MRI date.

Characteristic	Count or Mean (N=42,059)
Female	21895 (52.1%)
Age, years	55.1 (7.5)
British white ancestry	40675 (96.7%)
BMI, kg/m^2	26.1 (23.7, 28.9)
Systolic blood pressure, mmHg	135.0 (124.0, 148.0)
Diastolic blood pressure, mmHg	81.0 (74.0, 88.0)
Smoked ever	12840 (30.5%)
Alcohol intake frequency, drinks per week	2.0 (2.0, 3.0)
Total cholesterol, mmol/L	4.58 (4.00, 5.17)
LDL cholesterol, mmol/L	3.54 (3.00, 4.11)
HDL cholesterol, mmol/L	1.43 (1.20, 1.70)
Triglyceride, mmol/L	1.40 (0.99, 2.02)
Hyperlipidemia*	7010 (16.7%)

Type 2 diabetes*	1243 (3.0%)
Hypertension*	10082 (24.0%)
Prevalent CAD*	1987 (4.7%)
Incident CAD*	993 (2.4%)

Extraction of splenic radiomics features with deep learning

42,059 abdominal MRIs from UK biobank

nnuNet model to segment spleens

107 radiomics features extracted (e.g., sphericity)

Predictive modeling to identify splenic features associated with CAD

CAD

Splenic features

Identification of genetic variants associated with splenic features

Sphericity GWAS, 92 significant loci

$-\log_{10} p$-value

Chromosome

Prioritization of causal gene

Nearest gene

SNP

Gene

Polygenic priority score (PoPS)

Networks Pathways RNA-Seq

A → B → C

UMAP

Expression quantitative trait loci (eQTL)

Disease SNP

Gene X   Gene Y

SNP with associated tissue expression

Genetic overlap of SNPs for splenic features and CADs

CAD   Splenic features

nnuNet: No New U-Net; **CAD:** coronary artery disease; **SNP:** single nucleotide polymorphism

Figure 1. Summary of the workflow to identify splenic features associated with CAD and

discover genetic associations. First, radiomics features describing the spleen are extracted from

42,543 abdominal MRIs from the UK Biobank. Second, predictive models of each splenic

radiomic feature for CAD are implemented. Genome-wide association studies are then conducted

to identify genetic variants significantly associated with CAD-associated splenic radiomic

features. Based on the identified genetic variants, genes are then prioritized for further

investigation based on three different prioritization techniques: nearest gene, PoPS, and eQTL.

Finally, the genetic variants that were associated with splenic radiomics were investigated for

association with CAD using summary-level CAD GWAS meta-analysis. PoPs, polygenic priority

score. eQTL, expression quantitative trait loci. nnuNet, No New U-Net. CAD, coronary artery

disease. SNP, single nucleotide polymorphism. Reproduced by kind permission of UK Biobank

©.

1st order statistics
Distribution of voxel intensitites in image (18 features)
— Energy —
High | Low

3-D shape
Size and shape based on triangle mesh (14 features)
— Sphericity —
High | Low

Gray-level co-occurrence matrix
Intensities and spatial relationships of pixel pairs (16 features)
— Correlation —
High | Low

Gray-level size zone matrix
Quantifies areas of voxels with same intensity (16 features)
— Gray-level non-uniformity —
High | Low

Gray-level run length matrix
Measures length of voxel areas with same intensity (16 features)
- Run-length non-uniformity —
High | Low

Neighboring gray-tone difference matrix
Compares intensities of a voxel and its neighbors (5 features)
— Busyness —
High | Low

Gray-level dependence matrix
Quantifies adjacent voxels with similar intensities as center voxel (14 features)
Small dependence high gray emphasis
High | Low

588 **Figure 2. Categorization of Extracted Splenic Radiomics Features.** 7 categories of radiomic features with descriptions, numbers of

589 quantified features, and visualizations of high and low values for a selected feature. Reproduced by kind permission of UK Biobank ©.

Figure 3. Coefficients of BMI in a linear regression model for each splenic feature, adjusting for age and sex. Splenic radiomic features are grouped and colored by category using the color scheme from Figure 2. Features are grayed out if the Bonferroni corrected p-value for the coefficient of the BMI feature is greater than or equal to 0.05.

Figure 4. Splenic radiomics features selected by prediction models for prevalent and incident CAD. a) Splenic radiomics

features that were nominally associated (p-value < 0.05) with the prevalent CAD in a logistic regression model. b) Splenic radiomic

features that were also nominally associated with incident CAD in a Cox regression survival analysis model among those without

prevalent CAD. Covariates for both models included age, race, sex, and a set of splenic features chosen by forward stepwise

regression, to ensure that no splenic features in the model were significantly correlated with each other. c) Correlations of the fourteen

nominally significant splenic features across both models with conventional CAD risk factors. The Pearson correlation coefficient is

shown for correlations that are significant.

Higher gray non-uniform, gray level variance, and run-length non-uniformities values are associated with increased texture variation.

Correlation refers to the correlation between voxel locations and their gray level intensities. A higher energy value indicates higher

gray intensities. Higher small dependence high gray level emphasis indicates increased variation of areas of high gray levels. Higher

large low gray level emphasis indicate decreased variation of areas of low gray levels respectively. Higher inverse difference reflects

decreased texture variation of the spleen.

Feature abbreviations are as follows: Coronary Artery Disease, CAD. Energy, firstorder_Energy. Sphericity, shape_Sphericity.

Figure 5. Circular Manhattan plots from GWAS with 14 splenic phenotypes and CAD. a)

The circular Manhattan plot portrays the features that were statistically significant for prevalent

CAD. From outside to inside, the features are CAD, GLCM inverse difference, GLRLM run

length non-uniformity, GLSZM large area low gray level emphasis, GLDM gray level variance,

GLDM small dependence high gray level emphasis, energy, GLCM correlation, sphericity, and

GLSZM gray level-non uniformity. Red dots indicate significant loci. The y-axis is the log10 of

the p-value. b) The circular plot shows the features statistically significant for incident CAD.

From outside to inside, the features are CAD, GLRLM run length non-uniformity, and GLCM

inverse difference normalized. Feature abbreviations are as follows: CAD, Coronary Artery

Disease. Correlation, glcm_Correlation. Energy, firstorder_Energy. Sphericity, shape_Sphericity.

Figure 6. Genes prioritized for CAD-associated splenic radiomics. Genes were only included

if they were prioritized by at least two methods (out of nearest gene, eQTL, PoPS) for at least

one of the fourteen CAD-associated splenic phenotypes. Genes are grouped by the most

associated splenic phenotypes from left to right. In addition, genes prioritized by similar

phenotypes are grouped together.

Feature abbreviations are as follows: Correlation, glcm_Correlation. Energy, firstorder_Energy.

Sphericity, shape_Sphericity.

References

1. Ralapanawa, U. & Sivakanesan, R. Epidemiology and the Magnitude of Coronary Artery

Disease and Acute Coronary Syndrome: A Narrative Review: *J. Epidemiol. Glob. Health* **11**,

169 (2021).

2. Vaduganathan, M., Mensah, G. A., Turco, J. V., Fuster, V. & Roth, G. A. The Global Burden

of Cardiovascular Diseases and Risk. *J. Am. Coll. Cardiol.* **80**, 2361–2371 (2022).

3. Soehnlein, O. & Libby, P. Targeting inflammation in atherosclerosis — from experimental

insights to the clinic. *Nat. Rev. Drug Discov.* **20**, 589–610 (2021).

4. Ridker, P. M. *et al.* Antiinflammatory Therapy with Canakinumab for Atherosclerotic

Disease. *N. Engl. J. Med.* **377**, 1119–1131 (2017).

5. Yu, Z. *et al.* Genome-wide pleiotropy analysis of coronary artery disease and pneumonia

identifies shared immune pathways. *Sci. Adv.* **8**, eabl4602 (2022).

6. Heusch, G. The Spleen in Myocardial Infarction. *Circ. Res.* **124**, 26–28 (2019).

7. Dennis Robinette, C. & Fraumeni, JosephF. SPLENECTOMY AND SUBSEQUENT

MORTALITY IN VETERANS OF THE 1939-45 WAR. *The Lancet* **310**, 127–129 (1977).

8. Libby, P., Nahrendorf, M. & Swirski, F. K. Leukocytes Link Local and Systemic

Inflammation in Ischemic Cardiovascular Disease. *J. Am. Coll. Cardiol.* **67**, 1091–1103

(2016).

9. Dutta, P. *et al.* Myocardial infarction accelerates atherosclerosis. *Nature* **487**, 325–329 (2012).

10.   Van Der Laan, A. M. *et al.* Monocyte subset accumulation in the human heart following

acute myocardial infarction and the role of the spleen as monocyte reservoir. *Eur. Heart J.* **35**,

376–385 (2014).

11.   Emami, H. *et al.* Splenic Metabolic Activity Predicts Risk of Future Cardiovascular

Events. *JACC Cardiovasc. Imaging* **8**, 121–130 (2015).

12.   Bon-Baret, V. *et al.* System Genetics Including Causal Inference Identify Immune

Targets for Coronary Artery Disease and the Lifespan. *Circ. Genomic Precis. Med.* **14**,

e003196 (2021).

13.   Xu, P. *et al.* Radiomics: The Next Frontier of Cardiac Computed Tomography. *Circ.*

Cardiovasc. Imaging **14**, e011747 (2021).

14.   Enke, J. S. *et al.* Radiomics Features of the Spleen as Surrogates for CT-Based

Lymphoma Diagnosis and Subtype Differentiation. *Cancers* **14**, 713 (2022).

15.   Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.

Nature **562**, 203–209 (2018).

16.   Honigberg, M. C. *et al.* Long-Term Cardiovascular Risk in Women With Hypertension

During Pregnancy. *J. Am. Coll. Cardiol.* **74**, 2743–2754 (2019).

17.   Littlejohns, T. J. *et al.* The UK Biobank imaging enhancement of 100,000 participants:

rationale, data collection, management and future directions. *Nat. Commun.* **11**, 2624 (2020).

18.   Kart, T. *et al.* Automated imaging-based abdominal organ segmentation and quality

control in 20,000 participants of the UK Biobank and German National Cohort Studies. *Sci.*

Rep. **12**, 18733 (2022).

19.   Kart, T. *et al.* Deep Learning-Based Automated Abdominal Organ Segmentation in the

UK Biobank and German National Cohort Magnetic Resonance Imaging Studies. *Invest.*

Radiol. **56**, 401–408 (2021).

20.   Gatidis, S. *et al.* Better Together: Data Harmonization and Cross-Study Analysis of

Abdominal MRI Data From UK Biobank and the German National Cohort. *Invest. Radiol.* **58**,

346–354 (2023).

675   21.   van Griethuysen, J. J. M. *et al.* Computational Radiomics System to Decode the

676   Radiographic Phenotype. *Cancer Res.* **77**, e104–e107 (2017).

677   22.   Liu, Y. *et al.* Genetic architecture of 11 organ traits derived from abdominal MRI using

678   deep learning. *eLife* **10**, e65554 (2021).

679   23.   The 1000 Genomes Project Consortium *et al.* A global reference for human genetic

680   variation. *Nature* **526**, 68–74 (2015).

681   24.   Watanabe, K., Taskesen, E., Van Bochoven, A. & Posthuma, D. Functional mapping and

682   annotation of genetic associations with FUMA. *Nat. Commun.* **8**, 1826 (2017).

683   25.   Mountjoy, E. *et al.* An open approach to systematically prioritize causal variants and

684   genes at all published human GWAS trait-associated loci. *Nat. Genet.* **53**, 1527–1533 (2021).

685   26.   Weeks, E. M. *et al.* Leveraging polygenic enrichments of gene features to predict genes

686   underlying complex traits and diseases. *Nat. Genet.* **55**, 1267–1276 (2023).

687   27.   The International Mouse Phenotyping Consortium *et al.* High-throughput discovery of

688   novel developmental phenotypes. *Nature* **537**, 508–514 (2016).

689   28.   Groza, T. *et al.* The International Mouse Phenotyping Consortium: comprehensive

690   knockout phenotyping underpinning the study of human disease. *Nucleic Acids Res.* **51**,

691   D1038–D1045 (2023).

692   29.   Aragam, K. G. *et al.* Discovery and systematic characterization of risk variants and genes

693   for coronary artery disease in over a million participants. *Nat. Genet.* **54**, 1803–1815 (2022).

694   30.   Fairley, S., Lowy-Gallego, E., Perry, E. & Flicek, P. The International Genome Sample

695   Resource (IGSR) collection of open human genomic variation resources. *Nucleic Acids Res.*

696   **48**, D941–D947 (2020).

31.   Staley, J. R. *et al.* PhenoScanner: a database of human genotype-phenotype associations.

Bioinforma. Oxf. Engl. **32**, 3207–3209 (2016).

32.   Kamat, M. A. *et al.* PhenoScanner V2: an expanded tool for searching human genotype-

phenotype associations. *Bioinforma. Oxf. Engl.* **35**, 4851–4853 (2019).

33.   Schizophrenia Working Group of the Psychiatric Genomics Consortium *et al.* LD Score

regression distinguishes confounding from polygenicity in genome-wide association studies.

Nat. Genet. **47**, 291–295 (2015).

34.   Lavdas, I. *et al.* Machine learning in whole-body MRI: experiences and challenges from

an applied study using multicentre data. *Clin. Radiol.* **74**, 346–356 (2019).

35.   Lorensen, W. E. & Cline, H. E. Marching cubes: A high resolution 3D surface

construction algorithm. in *Proceedings of the 14th annual conference on Computer graphics*

and interactive techniques 163–169 (ACM, 1987). doi:10.1145/37401.37422.

36.   Alaa, A. M., Bolton, T., Di Angelantonio, E., Rudd, J. H. F. & Van Der Schaar, M.

Cardiovascular disease risk prediction using automated machine learning: A prospective study

of 423,604 UK Biobank participants. *PLOS ONE* **14**, e0213653 (2019).

37.   Zhuang, Y. *et al.* Circadian clocks are modulated by compartmentalized oscillating

translation. *Cell* **186**, 3245-3260.e23 (2023).

38.   Fjorder, A. S. *et al.* Haploinsufficiency of ARHGAP42 is associated with hypertension.

Eur. J. Hum. Genet. **27**, 1296–1303 (2019).

39.   Wafa, D. *et al.* Opposing Roles of S1P3 Receptors in Myocardial Function. *Cells* **9**, 1770

(2020).

40.   GTEx Consortium. Genetic effects on gene expression across human tissues. *Nature* **550**,

204–213 (2017).

41.   Mobeen Zafar, M. *et al.* 9p21 Locus Polymorphism Is A Strong Predictor of Metabolic

Syndrome and Cardiometabolic Risk Phenotypes Regardless of Coronary Heart Disease.

Genes **13**, 2226 (2022).

42.   Wellcome Trust Case Control Consortium *et al.* Genome-wide association study

identifies eight loci associated with blood pressure. *Nat. Genet.* **41**, 666–676 (2009).

43.   Vancauwenberghe, T., Snoeckx, A., Vanbeckevoort, D., Dymarkowski, S. &

Vanhoenacker, F. Imaging of the spleen: what the clinician needs to know. *Singapore Med. J.*

56, 133–144 (2015).

44.   Zhang, X.-J. *et al.* Association between single nucleotide polymorphisms in

thrombospondins genes and coronary artery disease: A meta-analysis. *Thromb. Res.* **136**, 45–

51 (2015).

45.   Dang, T. A. *et al.* Identification of a Functional *PDE5A* Variant at the Chromosome 4q27

Coronary Artery Disease Locus in an Extended Myocardial Infarction Family. *Circulation*

144, 662–665 (2021).

46.   Nurnberg, S. T. *et al.* Coronary Artery Disease Associated Transcription Factor TCF21

Regulates Smooth Muscle Precursor Cells That Contribute to the Fibrous Cap. *PLOS Genet.*

11, e1005155 (2015).

47.   Holdt, L. M. & Teupser, D. Recent Studies of the Human Chromosome 9p21 Locus,

Which Is Associated With Atherosclerosis in Human Populations. *Arterioscler. Thromb. Vasc.*

Biol. **32**, 196–206 (2012).